Vineet Laboratories Limited has announced a revision to its rights issue timeline, extending key dates to provide additional time for investors to participate in the offering.

Rights Issue Committee Decision

The Rights Issue Committee of the Board of Directors convened on January 13, 2026, from 12:00 Noon to 1:00 P.M. to deliberate on the rights issue schedule. The committee unanimously decided to extend both the last date for on-market renunciation and the issue closing date for the benefit of investors.

Revised Timeline Details

The company has modified two critical dates in its rights issue schedule:

Complete Revised Issue Schedule

The comprehensive timeline for the rights issue now follows this updated schedule:

Important Guidelines for Shareholders

The company has provided specific instructions for eligible equity shareholders regarding the renunciation process. Shareholders opting for off-market transfer renunciation must ensure completion of the process such that rights entitlements are credited to the demat account of the renouncee on or before the issue closing date of January 30, 2026.

Regulatory Compliance

This announcement has been made under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has duly informed both BSE Limited (Scrip Code: 543298) and National Stock Exchange of India Limited (Scrip Code: VINEETLAB) about these timeline modifications. The decision was communicated by Managing Director Gaddam Venkata Ramana (DIN: 00031873) through official regulatory filings.

Rights Issue Terms Finalized

Vineet Laboratories Limited has announced the complete terms for its rights issue following the Rights Issue Committee meeting held on December 17, 2025. The committee meeting, which commenced at 2:00 PM and concluded at 3:00 PM, finalized all key parameters including the record date of December 23, 2025, for determining eligible shareholders and confirmed the issue price at ₹30.00 per share.

Rights Entitlement ISIN Declared

The company has now disclosed the International Securities Identification Number (ISIN) for the Rights Entitlements as INE505Y20010, completing the regulatory framework for the upcoming rights issue. This announcement was made in accordance with SEBI circulars and Regulation 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Newspaper Publication Compliance

Vineet Laboratories has fulfilled its regulatory obligation under Regulation 84 of SEBI ICDR Regulations by publishing newspaper advertisements on December 29, 2025. The advertisements, confirming the completion of dispatch of Letter of Offer and Composite Application Forms, were published in three newspapers with wide circulation to ensure comprehensive investor awareness.

Issue Structure and Timeline

The rights issue will offer 99,87,258 fully paid-up equity shares with an entitlement ratio of 13:12, meaning eligible shareholders will receive 13 new rights equity shares for every 12 shares held on the record date. The issue is scheduled to open on January 1, 2026, and close on January 21, 2026, with the full amount of ₹30.00 per share payable on application.

Shareholding Impact and Next Steps

The rights issue will significantly expand the company's equity base from the current outstanding equity shares of 92,19,008 to 1,92,06,266 shares, assuming full subscription. The Rights Entitlements of eligible equity shareholders as on the record date will be credited prior to the issue opening date in their respective demat accounts under the declared ISIN INE505Y20010.